anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Physiotherapy interventions effectively improved fatigue and physical functioning in non-COVID patients with myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS). There is a research gap on the effectiveness of physiotherapy interventions versus drug management on ME/CFS in post-COVID-19 conditions (PCC).
METHODS: We planned a three-arm prospective randomized control trial on 135 PCC cases with ME/CFS who are diagnosed between 20 November 2023 and 20 May 2024 from a population-based cohort. The study aims to determine the effectiveness of physiotherapy interventions as adapted physical activity and therapeutic exercise (APTE) provided in institution-based care versus telemedicine compared with drug management (DM). Participants will be assigned to three groups with the concealed location process and block randomization with an enrollment ratio of 1:1:1. The post-treatment evaluation will be employed after 2 months of interventions, and follow-up will be taken after 6 months post-intervention. The Chalder fatigue scale will measure the primary outcome of fatigue. SF-36 and the disability-adjusted life years (DALYs) will measure the secondary outcome of physical functioning and episodic disability.
DISCUSSION: This study will address the research gap to determine the appropriate approach of physiotherapy or drug management for ME/CFS in PCC cases. The future direction of the study will contribute to developing evidence-based practice in post-COVID-19 condition rehabilitation.
TRIAL REGISTRATION: The trial is registered prospectively from a primary Clinical Trial Registry side of WHO CTRI/2024/01/061987. Registered on 29 January 2024.
Methods: In the study, 80 patients were randomly assigned to the study and control groups. Nursing interventions will be applied to the patients included in the study group (n=40), starting from the 0th day (the first day spent in the intensive care unit) after the thoracotomy in line with the prepared care protocol application steps until discharge. maintenance protocol; It will consist of position of the patient, mobilization, use of spirometer and shoulder exercises. The primary outcome of the research is the effect of the maintenance protocol used in the improvement of respiratory function on respiratory function tests. The secondary outcome of the research is to determine the effect of the care protocol on mobilization, complication development status, chest tube removal and discharge time in patients. The results are obtained by recording PFT values on the 1st, 5th and discharge days before and after thoracotomy. Postoperative (0.,1.,2.,3.,4.,5.) days and discharge day; mobilization, complication development status, chest tube removal time and discharge date will be recorded on the Patient Results Form.
This post-marketing study will enroll approximately 5,200 subjects 2-17 years of age who are seeking care in an outpatient setting for febrile acute respiratory illness. This study will begin in the fall of 2013 and will be completed after 4 influenza seasons (i.e.after the 2016-2017 influenza season). No investigational product will be administered in this study. A nasal swab will be obtained and tested for the presence of influenza virus and other viral pathogens. This study will be conducted at 4 sites in the United States of America. The duration of study participation for each subject is one day.
Methods and devices are provided for collecting input information from a user. Prompts are presented to said user through a user interface to make said user provide input information. The input information is processed to provide data, which is transmitted through a telecommunications interface to one or more remote processing arrangements. Images are taken of a face of said user when input information was provided by said user through said user interface. Microexpressions are detected from said taken images, and information indicative of said microexpressions is derived and stored as mood information. The mood information stored in association with temporally separate instances of said user providing said input information is compared, and trend information is derived indicative of results of such comparing. Said trend information transmitted through said telecommunications interface.
The invention provides a kind of device γ -lactone-enantiomer-kaurane diterpene (new compound cafarolide J), pharmaceutical composition and preparation method thereof, and application thereof in preparing medicine and food. Belongs to the technical field of medicines and foods. Novel compound Caffarolide J pairs of the invention α IC of glucosidase inhibitory activity  50  1.68.+ -. 0.01, as in the experiment with Accarbose IC  50  (mu M) 60.71.+ -. 16.45. The experimental results show that: compound caffeolide J pair α Glucosidase inhibitory Activity ratio first-line clinical α The glucosidase inhibitory drug Acarbose is stronger. The novel compound Caffarolide J can be used as a medicament for treating diabetes related diseases. Can be used for preparing health products for lowering blood sugar. The preparation method has the advantages of easily obtained raw materials, easy operation and high yield, and is suitable for industrial production.
BACKGROUND: The respiratory tract microbiome is essential for human health and well-being and is determined by genetic, lifestyle, and environmental factors. Patients with Common Variable Immunodeficiency (CVID) suffer from respiratory and intestinal tract infections, leading to chronic diseases and increased mortality rates. While CVID patients' gut microbiota have been analyzed, data on the respiratory microbiome ecosystem are limited.
OBJECTIVE: This study aims to analyze the bacterial composition of the oropharynx of adults with CVID and its link with clinical and immunological features and risk for respiratory acute infections.
METHODS: Oropharyngeal samples from 72 CVID adults and 26 controls were collected in a 12-month prospective study. The samples were analyzed by metagenomic bacterial 16S ribosomal RNA sequencing and processed using the Quantitative Insights Into Microbial Ecology (QIME) pipeline. Differentially abundant species were identified and used to build a dysbiosis index. A machine learning model trained on microbial abundance data was used to test the power of microbiome alterations to distinguish between healthy individuals and CVID patients.
RESULTS: Compared to controls, the oropharyngeal microbiome of CVID patients showed lower alpha- and beta-diversity, with a relatively increased abundance of the order Lactobacillales, including the family Streptococcaceae. Intra-CVID analysis identified age >45 years, COPD, lack of IgA, and low residual IgM as associated with a reduced alpha diversity. Expansion of Haemophilus and Streptococcus genera was observed in patients with undetectable IgA and COPD, independent from recent antibiotic use. Patients receiving azithromycin as antibiotic prophylaxis had a higher dysbiosis score. Expansion of Haemophilus and Anoxybacillus was associated with acute respiratory infections within six months.
CONCLUSIONS: CVID patients showed a perturbed oropharynx microbiota enriched with potentially pathogenic bacteria and decreased protective species. Low residual levels of IgA/IgM, chronic lung damage, anti antibiotic prophylaxis contributed to respiratory dysbiosis.
Ischemic heart disease is a crucial issue during pregnancy. The term is composed of both preexisting conditions and acute coronary syndrome in pregnancy, including pregnancy-associated myocardial infarction, which can have a significant effect on maternal and fetal outcomes. This review provides a complete guide to managing ischemic heart disease in pregnant women, emphasizing the importance of multidisciplinary care and individualized treatment strategies. Cardiovascular disease, particularly ischemic heart disease, is now the leading cause of maternal mortality worldwide. Pregnancy introduces unique physiological changes that increase the risk of acute myocardial infarction, with pregnancy-associated myocardial infarction cases often associated with factors, such as advanced maternal age, chronic hypertension, and preexisting cardiovascular conditions. This review distinguishes between preexisting ischemic heart disease and pregnancy-associated myocardial infarction. It will emphasize the various etiologies of pregnancy-associated myocardial infarction, including coronary atherosclerosis and plaque rupture presenting as ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and other nonatherosclerotic causes, including spontaneous coronary artery dissection, vasospasm, and embolism. Our study discusses the practical management of ischemic heart disease in pregnancy, with a focus on preconception counseling, risk assessment, and tailored antenatal planning for women with preexisting ischemic heart disease. Moreover, this document focuses on the challenges of diagnosing cardiovascular disease, especially when presented with nonclassical risk factors and presentation. It provides insight into the appropriate diagnostic testing methods, such as electrocardiogram, cardiac biomarkers, and echocardiography. In addition, the review covers various treatment strategies, from medical management to more invasive procedures, including coronary angiography, percutaneous coronary intervention, and coronary artery bypass graft. Special attention is given to medication safety during pregnancy, including anticoagulation, beta-blockers, and antiplatelet agents. The complexities of delivery planning in women with ischemic heart disease are discussed, advocating for a multidisciplinary team-based approach and careful consideration of the timing and mode of delivery. Furthermore, the roles of breastfeeding and postpartum care are explored, emphasizing the long-term benefits and the suitability of various medications during lactation. Lastly, this review provides crucial insights into the management of ischemic heart disease in pregnancy, stressing the need for heightened awareness, prompt diagnosis, and tailored management to optimize maternal and fetal health outcomes.
The invention relates to the field of medicine and pharmaceutics and, more specifically, to the creation of a pharmaceutical composition in the form of a suspension for the prevention and treatment of disorders in the physiological and reparative regeneration of tissues of the musculoskeletal system, i.e. osseous tissue and articular cartilage. The pharmaceutical compositions stimulating the regeneration of the osseous tissue and articular cartilage comprise the substance "Micellate of calcium and magnesium carbonates". The conducted trials have shown that the proposed pharmaceutical compositions have an apparent specific pharmacological activity, exhibiting a reparative and regenerative effect with respect to bone tissue in animals, and do not have a marked general toxic effect in different doses and routes of administration to laboratory animals. The compositions do not exhibit an irritant effect, and no sensitizing effect has been observed. The proposed pharmaceutical compositions are effective and safe and can be used to prevent and treat disorders in the physiological and reparative regeneration of tissues of the musculoskeletal system,  inter alia  in diabetes mellitus patients.
The present invention relates to a method for preparation of an active immunoadsorbent carrier. The active immunoadsorbent carrier is N, O-succinyl ethylene glycol chitosan prepared with glycol chitosan as monomer with succinic anhydride as acylating agent through acylation of water-soluble glycol chitosan. The active immunoadsorbent carrier is an amphipathic cationic polymer, has super high bioadhesive and adsorption promoting characteristic, and can easily combine with a negatively charged peptide drugs, genes, and vaccines. N, O-succinyl ethylene glycol chitosan polymer with a particular degree of substitution can be synthesized by controlling reaction conditions and feeding proportion. The polymer gel can be used as carrier of rheumatoid arthritis immunoadsorbent with adsorption clearance rate up to 60.9%, 63.5%, and 48.0%. N, O-succinyl ethylene glycol chitosan polymer gel can be used as a carrier to prepare immunosorbent, and has high selectivity, high adsorption efficiency, no adsorption of non-objective substance, no coagulation, no hemolysis, good blood compatibility, easy sterilization, good mechanical strength, and easy activation.
Subacromial impingement syndrome (SAIS) is a frequent cause of shoulder pain. Clinical trials investigating the effectiveness of manual therapy have demonstrated improvements in outcomes when manual therapy has been added to a program of therapeutic exercise. However, the these clinical trials (3) have significant limitations and generalizability. Two of the three 3 trials had a small number of subjects (14 \& 22 subjects) and all 3 trials had only short term follow up (\<12 weeks) and used non-validated self report outcome measures. These limitations reduce the confidence with which clinicians can apply these results to the patients they treat with SAIS. Clear evidence is needed to justify the cost and clinician time required to perform manual therapy in the delivery of patient care. Therefore, the purpose of this randomized clinical trial is to examine the short-term and long-term effectiveness of manual therapy in addition to therapeutic exercise as compared to therapeutic exercise only in patients diagnosed with SAIS.
The invention belongs to the field of medicine technology, and relates to a beta-elemene indole derivative and medicinal salts thereof. The beta-elemene indole derivative has the following structure. R represents H, CH3 and C2H5; and R1 represents F, Cl, Br, CH3, OCH3, NH2, OH, NO2 and phenyl, and cyclohexane skeleton has three chiral centers. The invention also relates to a preparation method of the compound and pharmaceutically acceptable salts thereof, and a composition containing the compound. The beta-elemene indole derivative and medicinal salts thereof in the invention have good anticancer activity, and the preparation method is simple, practical, and easy to operate. The structure is shown in the description.
The study consists of an initial visit coinciding with the start of treatment, a subsequent visit after 6 months of treatment and finally another after 12 months, coinciding with the end of treatment. In case of worsening after suspension, a clinical visit will be carried out at the time of worsening to evaluate the reintroduction of the drug and in case of reintroduction, a visit will be carried out after 3 months. If patients do not worsen, a visit will be made 6 months after completing treatment.

At each visit, demographic and clinical variables will be collected. In addition, 3 blood tests will be performed corresponding to the beginning of treatment, after 6 months and a month and a half from the last infiltration. Likewise, a brain MRI will be obtained prior to the start of treatment. These blood samples and neuroimaging data will be processed for subsequent analysis.
FIELD: biotechnology, pharmacy. SUBSTANCE: invention relates to ligand and methods of its specific binding with receptor stem of polymeric immunoglobulin (pIgR) of cell under condition that ligand does not bind secretory component pIgR under physiological conditions practically. Ligand can be directed on cell, into cell or for passing through its and can comprise biologically active substances. Invention can be used for delivery of therapeutic and diagnostic compositions on epithelial mucosa cells, into these cells or through their. EFFECT: improved method of incorporation, valuable properties of ligand. 28 cl
BACKGROUND: Lymphatic filariasis (LF) is a neglected tropical disease targeted for elimination as a public health problem by 2030. Although mass treatments have led to huge reductions in LF prevalence, some countries or regions may find it difficult to achieve elimination by 2030 owing to various factors, including local differences in transmission. Subnational projections of intervention impact are a useful tool in understanding these dynamics, but correctly characterizing their uncertainty is challenging.
METHODS: We developed a computationally feasible framework for providing subnational projections for LF across 44 sub-Saharan African countries using ensemble models, guided by historical control data, to allow assessment of the role of subnational heterogeneities in global goal achievement. Projected scenarios include ongoing annual treatment from 2018 to 2030, enhanced coverage, and biannual treatment.
RESULTS: Our projections suggest that progress is likely to continue well. However, highly endemic locations currently deploying strategies with the lower World Health Organization recommended coverage (65%) and frequency (annual) are expected to have slow decreases in prevalence. Increasing intervention frequency or coverage can accelerate progress by up to 5 or 6 years, respectively.
CONCLUSIONS: While projections based on baseline data have limitations, our methodological advancements provide assessments of potential bottlenecks for the global goals for LF arising from subnational heterogeneities. In particular, areas with high baseline prevalence may face challenges in achieving the 2030 goals, extending the "tail" of interventions. Enhancing intervention frequency and/or coverage will accelerate progress. Our approach facilitates preimplementation assessments of the impact of local interventions and is applicable to other regions and neglected tropical diseases.
OBJECTIVE: To investigate the associations of body mass index (BMI) change and large for gestational age (LGA) among prepregnancy normal-weight women with and without gestational diabetes mellitus (GDM).
METHODS: The retrospective study including 9515 normal-weight pregnant women (1331 women with GDM and 8184 without GDM) was conducted in Fujian Maternity and Child Health Hospital in 2020. The BMI change was calculated as gestational weight gain in kilograms by maternal height in meters. The binary logistic regression, stratified analyses, restricted cubic spline models and additive interaction analysis were adopted to reveal the relationship between BMI change and LGA.
RESULTS: Pregnant women with GDM had a lower level of BMI change but a higher incidence of LGA compared with those without GDM. After adjustment for covariates variables, we found that the risk of LGA was associated with the highest quartile of BMI change (OR = 1.89, 95%CI:1.27-2.8 for GDM and OR = 1.48,95%CI:1.27-1.75 for non-GDM). There were significant linear relationships of BMI change and LGA with the inflection point of 5.096 and 5.401 kg/m2 in GDM and non-GDM groups. Significant additive interaction was observed between parity and BMI change level concerning LGA. A significant difference in BMI change and gestational weight gain (GWG) for LGA prediction was detected.
CONCLUSION: Higher BMI changes were significantly associated with a higher risk of LGA in pregnant women with or without GDM in a linear dose-response relationship, with the threshold around 5.096 and 5.401 kg/m2, respectively. These suggested that BMI changes may be a useful predictor for the incidence of LGA in singleton pregnant women.
The invention relates to a Chinese isolated strain of bovine enterovirus, and constructions and applications of infectious cDNA clone thereof. Isolated strain of bovine enterovirus capable of stably generating CPE on MA104 cells can be separated from bovine diarreal stool samples, with a microbial preservation number of CGMCC No. 4782. Whole-length infectious cDNA clone is constructed from the isolated strain. B family gene type 2 bovine enterovirus rescue virus is obtained by in-vitro transcribing the cDNA and transfectioning cells. The isolated strain of bovine enterovirus, the constructed whole-length infectious cDNA clone and the rescue virus thereof can be used for researches of gene structures and functions of bovine enterovirus, can be used as vaccine vectors of bovine enterovirus, or can be prepared into vaccines or reagents capable of preventing or treating bovine enterovirus.
Contamination of duodenoscopes is a significant concern due to the transmission of multidrug-resistant organisms (MDROs) among patients who undergo endoscopic retrograde cholangiopancreatography (ERCP), resulting in outbreaks worldwide. In July 2020, it was determined that three different patients, all had undergone ERCP with the same duodenoscope, were infected. Two patients were infected with blaCTX-M-15 encoding Citrobacter freundii, one experiencing a bloodstream infection and the other a urinary tract infection, while another patient had a bloodstream infection caused by blaSHV-12 encoding Klebsiella pneumoniae. Molecular characterization of isolates was available as every ESBL-producing isolate undergoes Next-Generation Sequencing (NGS) for comprehensive genomic analysis in our center. After withdrawing the suspected duodenoscope, we initiated comprehensive epidemiological research, encompassing case investigations, along with a thorough duodenoscope investigation. Screening of patients who had undergone ERCP with the implicated duodenoscope, as well as a selection of hospitalized patients who had ERCP with a different duodenoscope during the outbreak period, led to the discovery of three additional cases of colonization in addition to the three infections initially detected. No microorganisms were detected in eight routine culture samples retrieved from the suspected duodenoscope. Only after destructive dismantling of the duodenoscope, the forceps elevator was found to be positive for blaSHV-12 encoding K. pneumoniae which was identical to the isolates detected in three patients. This study highlights the importance of using NGS to monitor the transmission of MDROs and demonstrates that standard cultures may fail to detect contaminated medical equipment such as duodenoscopes.
Patients with suspected Idiopathic Intracranial Hypertension (IIH) will be recruited and undergo an ophthalmologic investigation, and a lumbar puncture, both of which are necessary for diagnosis of IIH. MRI is done as a standard of care to rule out other etiologies of raised intracranial pressure. Our patients will require four MRI/MRVs. The first MRI/MRV is standard of care scan. The second MRI/MRV will be on the day of the lumber puncture, immediately following the procedure. The third MRI/MRV will take place when significant reduction of clinical papilledema has taken place (about 3-6 months), and a forth MRI will take place one year after the initial presentation or with symptom resolution, whichever comes first. Radiological findings will be compared at all stages to determine if transverse venous sinus stenosis can be reversed with standard of care medical treatment.
PURPOSE: A pharmaceutical composition containing a Selaginella tamariscina Spring extract or a fraction thereof is provided to prevent or treat asthma. CONSTITUTION: A pharmaceutical composition for preventing or treating asthma contains a Selaginella tamariscina Spring extract or a fraction thereof; and a pharmaceutically acceptable carrier. The extract is prepared using water, C1-C4 alcohol, or a mixture thereof. The C1-C4 alcohol is methanol or ethanol. The fraction is prepared form the extract using non-polar or polar organic solvent. [Reference numerals] (AA) Bronchus contraction inhibition rate(%); (BB) Selaginella tamariscina Spring extract; (CC) Hexane fraction; (DD) Chloroform fraction; (EE) Ethylacetate fraction; (FF) Butanol fraction